Affiliation:
1. Hospital Israelita Albert Einstein – HIAE, Brazil
2. Faculdade de Medicina do ABC – FMABC, Brazil
Abstract
The discovery of the Philadelphia chromosome in 1960, and of the BCR-ABL oncogene in 1984, enabled the development in subsequent years of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history. The use of imatinib resulted in a significant improvement of the prognosis and outcome of patients with chronic myeloid leukemia. However, the occurrence of mechanisms of resistance or intolerance precludes the eradication of the disease in some of the patients. Second-generation tyrosine-kinase inhibitors are efficient in most of these patients, except for those with T315I mutation. We present an overall review of chronic myeloid leukemia, with emphasis on the progress in its treatment.
Reference58 articles.
1. Natural history and staging of chronic myelogenous leukemia;Cortes J;Hematol Oncol Clin North Am,2004
2. A minute chromosome in human chronic granulocytic leukemia [abstract];Nowell PC;Science,1960
3. The story of chronic myeloid leukaemia;Geary CG;Br J Haematol,2000
4. Biology of chronic myelogenous leukemia––signaling pathways of initiation and transformation;Melo JV;Hematol Oncol Clin North Am,2004
5. The molecular biology of chronic myeloid leukemia;Deininger MW;Blood,2000
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献